Shot In The Arm: U.S. FDA Approves Ranbaxy's Finished Dose Unit At Mohali; Company May Shore Up Product Filings
This article was originally published in PharmAsia News
U.S. FDA clears Ranbaxy's Punjab manufacturing site, clearing the Indian company to start shipping products to the U.S. again as Lipitor mystery continues.
You may also be interested in...
FDA will lift a portion of its import alert for generic drugs made in two of Ranbaxy's facilities to allow the company to import antiviral ganciclovir to avoid a drug shortage
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.